Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)

Clinical trial NCT00240266 · COMPLETED

Trial details

NCT number: NCT00240266
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Metabolic Syndrome Dyslipidemia

Start date: 2003-08-01
Primary completion: 2004-11-01
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.